Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: The ESPLANADE trial

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 11, 2010, Pages 1928-1938

  Ruggenenti, Piero ^a,b   Perna, Annalisa ^a   Tonelli, Marcello ^a,c   Loriga, Giacomina ^a,d   Motterlini, Nicola ^a   Rubis, Nadia ^a   Ledda, Franca ^a,d   Rota Jr , Stefano ^a,b   Satta, Andrea ^d   Granata, Antonio ^e   Battaglia, Giovanni ^f   Cambareri, Francesco ^g   David, Salvatore ^h   Gaspari, Flavio ^a   Stucchi, Nadia ^a   Carminati, Sergio ^a   Ene Iordache, Bogdan ^a   Cravedi, Paolo ^a   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF SASSARI   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f Ospedale Acireale S Marta e S Venera   (Italy)

^g BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^h UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALBUMIN; ANGIOTENSIN RECEPTOR; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN B; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; POTASSIUM; TRIACYLGLYCEROL; VALSARTAN;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET THERAPY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PHARMACOLOGICAL BLOCKING; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; ITALY; KIDNEY DISEASES; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 78049392231     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03380410     Document Type: Article

References (37)

1. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17: 2034-2047, 2006
2. Ruggenenti P, Perna A, Remuzzi G: Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 63: 2254-2261, 2003 (Pubitemid 36605839)
3. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M: Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: Analysis of a previously conducted randomised trial. BMJ 332: 1426, 2006
4. Vaziri ND: Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262-F272, 2006
5. Brunskill NJ: Albumin signals the coming of age of proteinuric nephropathy. J Am Soc Nephrol 15: 504-505, 2004
6. Moorhead JF, Wheeler DC, Varghese Z: Glomerular structures and lipids in progressive renal disease. Am J Med 87: 12N-20N, 1989
7. Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M, Ruggenenti P, Remuzzi G: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 276: F457-F466, 1999
8. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63: 1094-1103, 2003
9. Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G: Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: Meta-analysis and metaregression. Am J Kidney Dis 52: 475-485, 2008
10. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G: Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 19: 1213-1224, 2008
11. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352: 1252-1256, 1998
12. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
13. Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, Cattaneo D, Remuzzi G: Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 107: 586-592, 2003
14. Vazquez-Perez S, Aragoncillo P, de Las Heras N, Navarro-Cid J, Cediel E, Sanz-Rosa D, Ruilope LM, Diaz C, Hernandez G, Lahera V, Cachofeiro V: Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Nephrol Dial Transplant 16 [Suppl 1]: 40-44, 2001
15. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G: How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach. J Am Soc Nephrol 13: 2898-2908, 2002
16. Ruan XZ, Varghese Z, Moorhead JF: An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 5: 713-721, 2009
17. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC: Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ 336: 645-651, 2008
18. Douglas K, O'Malley PG, Jackson JL: Meta-analysis: The effect of statins on albuminuria. Ann Intern Med 145: 117-124, 2006
19. Lee TM, Su SF, Tsai CH: Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 40: 67-73, 2002 (Pubitemid 34755981)
20. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570, 2003
21. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GF: HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev CD007784, 2009
22. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G: Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 6: 257-263, 1995
23. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103-115, 1975
24. Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 9: 2096-2101, 1998
25. Gheith OA, Sobh MA, Mohamed Kel S, El-Baz MA, El-Husseini F, Gazarin SS, Ahmed HA, Rasem MW, Amer GM: Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 91: 612-619, 2002
26. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35: 549-556, 1979
27. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 356: 147-152, 2000
28. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361: 2024-2031, 2003
29. Lee TM, Lin MS, Tsai CH, Chang NC: Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney Int 68: 779-787, 2005
30. Bautista LE: Blood pressure-lowering effects of statins: Who benefits? J Hypertens 27: 1478-1484, 2009
31. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553, 2008
32. Ruggenenti P, Remuzzi G: Proteinuria: Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 5: 436-437, 2009
33. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927, 2004
34. Doggrell SA: Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Rev Recent Clin Trials 1: 143-153, 2006
35. Farmer JA, Torre-Amione G: Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 23: 197-213, 2000
36. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P: Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 29: 253-260, 2007
37. Bevilacqua M, Righini V, Barrella M, Vago T, Chebat E, Dominguez LJ: Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes. Adv Ther 22: 527-542, 2005